Antifungal susceptibilities of Candida bloodstream isolates from two different Turkish hospitals
Abstract number: P2178
Yücesoy M., Ayhan Y., Irmak O., Gülfidan G., Özer S.
Background:Candida spp. are among the leading aetiologic agents of bloodstream infections in hospitalised patients. Antifungal susceptibilities of these isolates are very important for the management of patients with invasive candidiasis.
Objectives: This study was performed to investigate the in vitro antifungal susceptibility patterns of Candida bloodstream isolates from two different hospitals located in the same city.
Methods: A total number of 139 non duplicate Candida bloodstream isolates (49 C. albicans, 24 C. parapsilosis, 11 C. tropicalis, eight C. glabrata, three C. kefyr, three C. utilis, two C. guilliermondii, one C. famata, one C. krusei and one C. lusitaniae from Dokuz Eylul (DEU) hospital; 12 C. albicans, 16 C. parapsilosis, three C. famata, three C. pelliculosa and two C. guilliermondii from Dr Behcet Uz Children's Hospital (BU)) cultured within one year period were tested against amphotericin B, fluconazole and voriconazole using CLSI M27-A2 microdilution method. The identification of the isolates were done according to germ tube test, morphology on corn meal tween 80 agar and CHROMagar Candida and API 20C AUX system.
Results: The MIC50 and MIC90 values detected for C. albicans, C. parapsilosis, C. tropicalis and C. glabrata strains are shown in the table. All isolates except one C. lusitaniae were susceptible to amphotericin B. One C. krusei, one C. parapsilosis, three C. tropicalis isolates were resistant to fluconazole while the rest of the strains were susceptible. For voriconazole one C. albicans, two C. tropicalis and one C. utilis were detected to be resistant and one C. albicans was found as dose dependent susceptible.
Conclusion: According to our results it can be concluded that amphotericin B, fluconazole and voriconazole are detected to be active against our Candida bloodstream isolates and they remain to be appropriate choices for the treatment of patients with Candida bloodstream infections.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|